Chondrocyte knee disorder therapy - Isto Biologics

Drug Profile

Chondrocyte knee disorder therapy - Isto Biologics

Alternative Names: DeNovo ET; Neocartilage; RevaFlex

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator ISTO Technologies
  • Developer Isto Biologics
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cartilage disorders

Most Recent Events

  • 10 Mar 2016 Chondrocyte knee disorder therapy is still in phase III trials for Cartilage disorders in USA (Intra-articular)
  • 07 Feb 2012 Phase-III clinical trials in Cartilage disorders in USA (Intra-articular)
  • 15 Feb 2007 Phase-I/II clinical trials in Cartilage disorders in USA (Intra-articular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top